(OTKA139010) Támogató: Hungarian National Research, Development and Innovation Office
(TKP2021-EGA-25)
János Bolyai Research Scholarship of the Hungarian Academy of Sciences(TKP2021-NVA-15)
(OTKA PD 134449)
(TKP2021-EGA-02) Támogató: NKFIH
Hungarian Brain Research Program(2017-1.2.1-NKP-2017-00002) Támogató: NKFIH
(TKP2021-EGA-32) Támogató: NKFIH
Introduction Early-onset dementias (EOD) are predominantly genetically determined,
but the underlying disease-causing alterations are often unknown. The most frequent
forms of EODs are early-onset Alzheimer's disease (EOAD) and frontotemporal dementia
(FTD). Patients This study included 120 Hungarian patients with EOD (48 familial and
72 sporadic) which had a diagnosis of EOAD (n = 49), FTD (n = 49), or atypical dementia
(n = 22). Results Monogenic dementia was detected in 15.8% of the patients. A pathogenic
hexanucleotide repeat expansion in the C9ORF72 gene was present in 6.7% of cases and
disease-causing variants were detected in other known AD or FTD genes in 6.7% of cases
(APP, PSEN1, PSEN2, GRN). A compound heterozygous alteration of the TREM2 gene was
identified in one patient and heterozygous damaging variants in the CSF1R and PRNP
genes were detected in two other cases. In two patients, the coexistence of several
heterozygous damaging rare variants associated with neurodegeneration was detected
(1.7%). The APOE genotype had a high odds ratio for both the APOE e4/3 and the e4/4
genotype (OR = 2.7 (95%CI = 1.3-5.9) and OR = 6.5 (95%CI = 1.4-29.2), respectively).
In TREM2, SORL1, and ABCA7 genes, 5 different rare damaging variants were detected
as genetic risk factors. These alterations were not present in the control group.
Conclusion Based on our observations, a comprehensive, targeted panel of next-generation
sequencing (NGS) testing investigating several neurodegeneration-associated genes
may accelerate the path to achieve the proper genetic diagnosis since phenotypes are
present on a spectrum. This can also reveal hidden correlations and overlaps in neurodegenerative
diseases that would remain concealed in separated genetic testing.